Goodwill impairment of $8.3m drives HY24 loss of $10.9m

That charge is the largest single contributor to a reported net loss after tax of $10.9m, against a small profit of $0.7m in HY23.

Revenue from contracts with customers came in at just $17,000 for the half, with the canonical revenue movement at -100.0% versus the prior comparable. Operating cash outflow was $2.1m, an improvement on the prior period's $3.7m outflow, while capex was effectively nil at $1,208. Cash on hand finished at $1.0m and gross borrowings (lease liabilities) at $0.2m.

• The $8.3m write-down is non-cash, but it is a management admission that the deal economics did not materialise. That matters because the strategic case for the acquired capability now needs to be re-underwritten on standalone operating performance, not on goodwill carried at cost.
• Liquidity is the binding constraint. Cash of $1.0m against an HY24 operating outflow of $2.1m implies roughly six months of runway at the current burn rate, before any seasonal swing or working-capital movement. The slower burn versus HY23 helps, but does not remove the funding question.
• Revenue traction remains immaterial. With contracted revenue at $17,000 for the half and the release flagging total revenue of $141k down 44%, the commercial ramp implied by the German launch, the Target Health distribution agreement and the new Australian-based Chief of Sales and Marketing has not yet shown up in the numbers. The investment case still rests on future, not current, sales.

The supplied second-half shape is from FY23 and is not a reliable guide given the scale of the goodwill charge in HY24 and the very small revenue base; the implied FY23 second-half revenue of $0.3m relies on prior-period figures that do not translate cleanly to HY24's run rate.

What the release does support is a narrower read: management is repositioning around a "capital light" genetics-led export model, has signed distribution into new channels, and has appointed sales leadership in Australia. None of that has yet been quantified, so the gap between strategic narrative and reported revenue is the central tension into 2H24.

The $8.3m impairment is non-cash and explains why NPAT growth (-101.5%) and PBT growth (-101.5%) move in lockstep with no tax distortion (effective tax rate 0.0% in both periods). Stripping the impairment, the underlying operating loss is closer to $2.6m, broadly consistent with the $2.1m operating cash outflow.

The cash side is the more durable signal. Operating outflow narrowed materially versus HY23, capex was effectively switched off, and inventories were run down. That points to genuine cost discipline rather than a working-capital release flattering reported cash, but it also reflects an organisation that is shrinking its physical footprint while it waits for export revenue to land. ROE of -114.5% versus +2.7% prior is mechanically driven by the impairment against a small equity base ($9.5m) and should not be read as a run-rate return measure.

This briefing cannot assess management's internal forecasts for the impaired acquisition, the unit economics of the German and Australian channels, or the company's funding intentions, none of which are quantified in the release.